ClinicalTrials.gg

Program

axelopran

Also written as “TD-1211”, “TD-1211 IV [C14]” and “TD-1211 PO [C14]”.

Its studies are mostly in Opioid-Induced Constipation · Squamous Cell Carcinoma of Head and Neck · Constipation, led by Glycyx Therapeutics.

Furthest: phase 2, since Dec 22, 20098 company-led studies, 1 open or runningNext primary completion: Aug 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Glycyx Therapeutics81 open or runningphase 2since Dec 22, 2009Dec 22, 2009Aug 31, 2027phase 2 · NCT07662720

Also a collaborator on its studies: Zymeworks.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 22, 2009First study: phase 2 study in Opioid-Induced ConstipationFirst studyNCT01040637 · 102 enrolled · United States
  2. Mar 30, 2011Phase 2 study in Opioid-Induced ConstipationNCT01333540 · 69 enrolled · United States
  3. Jul 19, 2011Phase 2 study in Opioid-Induced ConstipationNCT01401985 · 95 enrolled · United States
  4. Oct 24, 2011Phase 2 study in Opioid-Induced ConstipationNCT01459926 · 217 enrolled · United States
  5. Mar 23, 2012Phase 1 study in HealthyNCT01568411 · 20 enrolled · United States
  6. Jul 31, 2012Phase 1 study in ConstipationNCT01655771 · 47 enrolled · United States
  7. Oct 2, 2012Phase 1 study in Opioid-Induced ConstipationNCT01702194 · 10 enrolled · United States
  8. Jun 12, 2026Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07662720 · 18 planned

Ahead

  1. Aug 31, 2027Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07662720

TargetBeta

OPRM1 →read by rule
“Mu opioid receptor antagonist”ChEMBL 37, by rule

Other programs on OPRM1

ProgramCompanyFurthest phaseStudies
OxycodoneruleMundipharmaphase 472
Naltrexoneruleorexigen-therapeutics-incphase 442
nalmefeneruleH. Lundbeckphase 420
NalbuphineruleTrevi Therapeuticsphase 420
MethadoneruleMerckphase 416
cebranopadolruleTris Pharmaphase 318
AlfentanilruleSichuan Kelun Pharmaceuticalphase 11

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07662720Squamous Cell Carcinoma of Head and Neck2Not yet recruitingAug 31, 202718
NCT01702194Opioid-Induced Constipation · United States1CompletedFeb 201310
NCT01655771Constipation · United States1CompletedFeb 201347
NCT01568411Healthy · United States1CompletedJun 201220
NCT01459926Opioid-Induced Constipation · United States2CompletedMay 2012217
NCT01401985Opioid-Induced Constipation · United States2CompletedMay 201295
NCT01333540Opioid-Induced Constipation · United States2CompletedMay 201269
NCT01040637Opioid-Induced Constipation · United States2CompletedOct 2010102

How it is read

Names in the registry

  • “TD-1211”, 15 entries
  • “axelopran”, 1 entry
  • “TD-1211 IV [C14]”, 1 entry
  • “TD-1211 PO [C14]”, 1 entry
  • “TD-1211+ itraconazole”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.